Innovating Women’s Reproductive Health Therapeutics

At ObsEva, our passion and expertise in reproductive health and pregnancy therapeutics is helping millions of women worldwide lead healthier and more fulfilling lives.

Learn more Latest Company Investor presentation

Clinical Studies

We are currently conducting six international clinical research studies.

Read more

Our Pipeline

Nolasiban

(OBE001)
Oral oxytocin
receptor antagonist

Next milestones

  • EU Phase 3 IMPLANT 4 Primary endpoint data Q4 2019
  • EU MAA filing planned late 2019
  •  US Phase 3 IMPLANT 3 Initiation Q4 2019 / Q1 2020

Commercial rights

  • Exclusive Worldwide
Learn more

Linzagolix

(OBE2109)
Oral GnRH
receptor antagonist

Next milestones

Uterine Fibroids

  • Phase 3 PRIMROSE 2&1, 24-week Primary endpoint data Q4 2019 / H1 2020
  • NDA targeted end of 2020

Endometriosis

  • Phase 2b EDELWEISS 1, 76-week Follow-up completion H2 2019
  • Phase 3 EDELWEISS 2&3 enrolment Q3 2019

Commercial rights

  • Exclusive Worldwide (ex-Asia)
Learn more

OBE022

Oral and selective
prostaglandin F2
alpha receptor antagonist

Next milestones

  • EU Phase 2a PROLONG Interim Efficacy Q4 2019

Commercial rights

  • Exclusive Worldwide
Learn more

ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

October 11, 2019

Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of…

Learn more

ObsEva in the media

Learn more

Other ObsEva press releases

Learn more
 

Work With Us

Are you ready to join an innovative biopharmaceutical company that’s advancing women’s reproductive health and pregnancy therapeutics? Currently we have no open vacancies but you can always join our talent community below.

Talent Community